CyGenics Signs Collaboration Agreement with the Blood Centre of Zhejiang Province
Research license for development work on CyGenics T cells technology
CyGenics Ltd signed an agreement with the Blood Centre of Zhejiang Province (ZBC) in China for development work generating human T cells outside the body for the treatment of HIV, using CyGenics' proprietary cellular growth technology. This cellular growth technology is owned by CyGenics' wholly owned subsidiary, Cytomatrix LLC. According to the company, CyGenics' patented three-dimensional growth scaffold, the Cytomatrix, has been shown in laboratory studies to be able to generate T cells - in effect, to become an artificial thymus.
As one of the premier blood centres in China, ZBC has ready access to all sources of haematopoietic stem cells, such as umbilical cord blood, bone marrow, and peripheral blood. The Centre will use stem cells donated for research to undertake a series of studies. Once completed ZBC may assess the feasibility of applying the technology for the treatment of HIV, subject to regulatory approval.
CyGenics will retain ownership of all intellectual property that may arise from this collaboration. ZBC may opt to license the technology from CyGenics, for use within the China market.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
